Klinikum Chemnitz

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) (2019) Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Luebbe K, et al. Journal article Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer (2019) Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fießler C, Hein A, et al. Journal article Clinical pharmacy services in Germany: A national survey (2019) Schulz C, Fischer A, Vogt W, Leichenberg K, Warnke U, Liekweg A, Georgi U, et al. Journal article Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019) Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, zu Eulenburg C, et al. Journal article Quality of life of short-statured children born small for gestational age or idiopathic growth hormone deficiency within one year of growth hormone treatment (2019) Quitmann J, Bloemeke J, Silva N, Bullinger M, Witt S, Akkurt I, Dunstheimer D, et al. Journal article Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients (2019) Nabieva N, Häberle L, Brucker SY, Janni W, Volz B, Löhberg C, Hartkopf AD, et al. Journal article Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) Middeke JM, Rollig C, Kramer M, Kramer A, Bochtler T, Scholl S, Hochhaus A, et al. Conference contribution EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) Stasik S, Middeke JM, Kraemer M, Rollig C, Kramer A, Scholl S, Hochhaus A, et al. Conference contribution Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases (2018) Wermann WK, Viardot A, Kayser S, Alakel N, Elmaagacli A, Faul C, Fiedler W, et al. Conference contribution Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, et al. Conference contribution